EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma

Lucía Santa Maria de la Parra iD, Matías H Assandri iD, Luisina M Solernó, María de Los A Serradell iD, Daniel F Alonso iD, Juan Garona iD, Lucía M Balsa iD, Ignacio E León iD

Pharmaceutics · 17.03.2026 · 18 (3) · 372

DOI: 10.3390/pharmaceutics18030372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 17.03.2026. Verfasst von Lucía Santa Maria de la Parra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Química Inorgánica (CEQUINOR CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Naci…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONICET, UNLP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults, with poor prognosis due to relapse, metastasis, and chemoresistance. The search for novel metal-based therapeutics has highlighted copper complexes as promising candidates. Here, we report the in vitro and in vivo antitumor activity of a tetranuclear Cu(II)-hydrazone complex (Cu4L4) derived from (E)-5-chloro-N′-(2-hydroxy-3-methoxybenzylidene)thiophene-2-carbohydrazide.

Results

Cytotoxic assays on MG-63 OS cells revealed potent activity with an IC50 of 0.50 ± 0.04 µM, significantly surpassing its free ligand (IC50 = 13.9 ± 1.6 µM) and cisplatin (IC50 = 39.0 ± 1.8 µM). This tetranuclear complex outperforms mononuclear Cu-hydrazones analogs (e.g., 4-fold vs. CuHL1, 2-fold vs. CuHL2, 5-fold vs. CuHL3, 17-fold vs. CuHL4,), and Cu4L4 also exhibits reduced clonogenic survival, induces reactive oxygen species production, and promotes late apoptosis as a main mechanism, being the main mechanism of action involved in anticancer activity. In multicellular tumor spheroids, the complex maintained strong cytotoxicity (IC50 = 4.11 ± 0.12 µM), impaired spheroid integrity, and markedly inhibited cell migration at sub-IC50 concentrations. The tetranuclear architecture confers markedly enhanced antitumor activity relative to the corresponding mononuclear Cu–hydrazone complexes (e.g., 2-fold vs. CuHL1, 4-fold vs. CuHL2, 2-fold vs. CuHL3). In a xenograft model, sustained administration of Cu4L4 (2 mg/kg, i.p., twice weekly) inhibited tumor growth by 43.6%, reduced mitotic index, and increased necrotic area without significant systemic toxicity.

Conclusions

Overall, Cu4L4 displayed potent and selective antitumor activity against OS cells in 2D, 3D, and in vivo models, underscoring copper–hydrazone complexes as promising scaffolds for the development of new therapies against OS.

Schlagwörter

Stichwörter der Autor:innen

coppermetallodrugosteosarcomapreclinical studies

Autor:innen und Institutionen

  • Centro de Química Inorgánica (CEQUINOR CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata B1900, Buenos Aires, Argentina.
  • Cátedra de Microbiología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata B1900, Buenos Aires, Argentina.
  • Centro de Oncología Molecular y Traslacional (COMTra), Universidad Nacional de Quilmes, Bernal B1876, Buenos Aires, Argentina.
  • Unidad de Investigación Biomédica en Cáncer (IBioCAN), Centro de Medicina Traslacional, Hospital de Alta Complejidad en Red El Cruce "Dr. Néstor Carlos Kirchner" S.A.M.I.C, Florencio Varela B1888, Buenos Aires, Argentin…
  • Instituto de Ciencias de la Salud, Universidad Nacional Arturo Jauretche (UNAJ), Florencio Varela B1888, Buenos Aires, Argentina.
  • Cátedra de Fisiopatología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata B1900, Buenos Aires, Argentina.

ORCID-Profile: Lucía Santa Maria de la Parra, Matías H Assandri, María de Los A Serradell, Daniel F Alonso, Juan Garona, Lucía M Balsa, Ignacio E León

Förderung

  • CONICET
  • UNLP

Zitieren

APA

Santa Maria de la Parra, L., Assandri, M. H., Solernó, L. M., Serradell, M. L. A., Alonso, D. F., Garona, J., Balsa, L. M., & León, I. E. (2026). In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma. Pharmaceutics, 18(3), 372. https://doi.org/10.3390/pharmaceutics18030372

Vancouver

Santa Maria de la Parra L, Assandri MH, Solernó LM, Serradell MLA, Alonso DF, Garona J, et al. In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma. Pharmaceutics. 2026;18(3):372. doi:10.3390/pharmaceutics18030372

BibTeX
@article{SantaMariadelaParra2026,
  author = {Santa Maria de la Parra, Lucía and Assandri, Matías H and Solernó, Luisina M and Serradell, María de Los A and Alonso, Daniel F and Garona, Juan and Balsa, Lucía M and León, Ignacio E},
  title = {In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {372},
  doi = {10.3390/pharmaceutics18030372}
}
Kostenlos starten →